MBX Biosciences (MBX) Equity Average (2023 - 2026)
MBX Biosciences has reported Equity Average over the past 4 years, most recently at $403.5 million for Q1 2026.
- Quarterly results put Equity Average at $403.5 million for Q1 2026, up 63.73% from a year ago — trailing twelve months through Mar 2026 was $403.5 million (up 63.73% YoY), and the annual figure for FY2025 was $313.3 million, up 238.79%.
- Equity Average reached $403.5 million in Q1 2026 per MBX's latest filing, up from $378.4 million in the prior quarter.
- Across five years, Equity Average topped out at $403.5 million in Q1 2026 and bottomed at -$90.5 million in Q2 2024.
- Median Equity Average over the past 4 years was $236.9 million (2025), compared with a mean of $167.3 million.
- The largest annual shift saw Equity Average skyrocketed 485.19% in 2024 before it soared 43.11% in 2025.
- Over 4 years, Equity Average stood at -$68.6 million in 2023, then surged by 485.19% to $264.4 million in 2024, then soared by 43.11% to $378.4 million in 2025, then increased by 6.64% to $403.5 million in 2026.
- Business Quant data shows Equity Average for MBX at $403.5 million in Q1 2026, $378.4 million in Q4 2025, and $303.4 million in Q3 2025.